	US 12,324,827 B2
	Combination therapy for the treatment of migraines
Richard Kraig, Chicago, IL (US); Lisa Won, Chicago, IL (US); Kae Pusic, Chicago, IL (US); Aya Pusic, Chicago, IL (US); and Martin Sanders, Chicago, IL (US)
Assigned to The University of Chicago, Chicago, IL (US); and Seurat Therapeutics, Chicago, IL (US)
Filed by The University of Chicago, Chicago, IL (US); and Seurat Therapeutics, Chicago, IL (US)
Filed on Sep. 9, 2020, as Appl. No. 16/948,219.
Claims priority of provisional application 62/946,122, filed on Dec. 10, 2019.
Claims priority of provisional application 62/897,686, filed on Sep. 9, 2019.
Prior Publication US 2021/0077591 A1, Mar. 18, 2021
Int. Cl. A61K 38/30 (2006.01); A61K 9/00 (2006.01); A61K 31/4545 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 38/28 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 25/04 (2006.01); A61P 25/06 (2006.01)

CPC A61K 38/30 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0043 (2013.01); A61K 31/4545 (2013.01); A61K 38/2073 (2013.01); A61K 38/217 (2013.01); A61K 38/28 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 25/04 (2018.01); A61P 25/06 (2018.01)]

11 Claims

1. A method for treating a chronic pain syndrome patient, the method comprising administering to the patient an effective amount of an insulin growth factor receptor (IGFR) activator; wherein the chronic pain syndrome comprises fibromyalgia or chronic fatigue syndrome; wherein the method comprises the treatment of widespread muscle pain; and wherein the method further comprises administration of a calcitonin gene-related peptide (CGRP) inhibitor.